Research programme: Alzheimer's disease therapeutics - KeyNeurotek AG

Drug Profile

Research programme: Alzheimer's disease therapeutics - KeyNeurotek AG

Alternative Names: SRN 003 Tau research programme; SRN-003-556

Latest Information Update: 26 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KeyNeurotek AG
  • Developer KeyNeurotek Pharmaceuticals AG
  • Class Carbazoles
  • Mechanism of Action Mitogen-activated protein kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 16 Jul 2004 Preclinical trials in Alzheimer's disease in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top